Skip to main content
IP Helpdesk logo
IP Helpdesk
Training and workshops

Overview of China’s Biopharma Sector: Market Access & IP Rights

The webinar will provide an overview of two main aspects of China’s biopharma ecosystem

  • Intellectual property
  • to

Practical information

When
to
Languages
English

Description

Overview of China’s Biopharma Sector: Market Access & IP Rights
Overview of China’s Biopharma Sector: Market Access & IP Rights

This training is organized in cooperation with the EU SME Centre, the China-Italy Chamber of Commerce, Confindustria Lombardia and the Life Science Cluster of Lombardia.

The webinar will provide an overview of two main aspects of China’s biopharma ecosystem:

  1. Market and regulations, including: Market trends; Regulations and market access; Increasing role of Chinese players; Challenges and opportunities for European companies
  2. IP rights protection, including: Overview of the Chinese law on IP protection for pharmaceuticals; Patent and design registration for diagnostic and treatment equipment; Preventative measures to minimise the risk of leaking technical secrets; Company and product brand protection

 

Agenda:

 

16:00 – 16:15 Opening remarks

Representative of China-Italy Chamber of Commerce / EU SME Centre / Confindustria Lombardia, Life Sciences Cluster
 

16:15 – 16:45 Overview of China’s biopharma ecosystem 

Valtero Canepa, General Manager, Shanghai Bracco Sine Pharmaceutical Corp. Ltd.
 

16:45 – 17:15 Key issues for IP rights protection in China’s biopharma sector 

XU Jian, China IP SME Helpdesk expert; Head of IP practice at the China office of Gowling WLG
 

17:15 – 17:30 Q&A 


About the speakers:

Valtero Canepa

Valtero Canepa was born in Italy in 1960, has two children and lives in Shanghai. Mr Canepa worked more than 33 years at the Bracco group, where he made his debut as a medical representative, taking on several roles including Global Marketing Director, Country Manager Italy and Project Leader for product development.

In 2013 he moved to China, where he is presently responsible for the mainland and Hong Kong business of the Group, including diagnostic contrast agents and medical devices, with total revenues of more than 120 million euros in 2020 and employing more than 400 people, including medical and regulatory, production, distribution and promotion, sales and business development.

Thanks to the different assignments in his long career, he developed a very extensive knowledge of the global healthcare market, both for pharmaceuticals and medical devices.

He is the presently Vice President of the China-Italy Chamber of Commerce (CICC) and he was among the founders of the Healthcare Working Group of the CICC

XU Jian

Dr. Jian Xu is a dually qualified Chinese lawyer and patent/trademark attorney. He currently heads up the intellectual property practice at the China office of Gowling WLG.

Dr. Jian Xu joined the firm in 2008 and has been the head of the intellectual property practice of its China office since that date. Prior to that, he was a senior patent attorney at China Sinda, one of the largest intellectual property law firms in Beijing. He has handled all aspects of IPR in business including drafting, prosecution, acquisition, enforcement and licensing of patents, trade marks and brand, design rights, copyright and content. He has conducted litigation and administrative actions against infringers all over China. He also has a strong background in the chemistry and life science sector, with a bachelor’s degree from Beijing and a PhD degree in Biochemistry from the University of Manchester.